drugset / Trial / NCT00171782

Hypertension and Cardiovascular Risk Factors

NCT00171782

Phase 4 Completed 76 enrolled Novartis
Non-randomizedSingle-groupOpen-labelTreatment

Summary

A study to evaluate the efficacy of valsartan+chydochlorothiazide in patients with stage 2 hypertension and cardiovascular risk factors.

Timeline

Start
2004-02
Primary completion
2004-12
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrochlorothiazide Unknown
Subject Valsartan Small molecule

Indications